The HIV epidemic is continuing to grow worldwide. Because no single prevention intervention is a panacea, multiple prevention strategies should be evaluated and made available as combination interventions as quickly as possible, including agents for pre-exposure prophylaxis (PrEP) for both men and women. Oral tenofovir disproxil fumarate/emtricitabine (TDF/FTC) was approved by the Food and Drug Administration (FDA) for PrEP in July 2012. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have offered interim guidance about the use of TDF/FTC as PrEP. While the TDF/FTC combination provides an exciting new prevention tool, alternative PrEP agentsRead More
Subscribe To Fenway Focus
Fenway Health has served the LGBT community, those affected by HIV, and our other members of our community in Boston’s Fenway neighborhood and beyond for the last 40 years. Learn more about Fenway Health; our research arm, The Fenway Institute; and the Sidney Borum, Jr. Health Center, which provides safe, non-judgmental care for young people ages 12–29 who may not feel comfortable going anywhere else.
Affordable Care Act AIDS AIDS2012 AIDS Action Committee AIDS Walk Boston behavioral health bisexual Construction Update Events Fundraisers Gender identity Harbor to the Bay Health care Health Disparities HIV HIV/AIDS HIV/AIDS Policy HIV prevention HIV Research HIV testing International AIDS Conference Lesbian health LGBT advocacy LGBT Aging Project LGBT health LGBT Health Research LGBT seniors LGBT Youth Mentions in the news men who have sex with men National LGBT Health Education Center news Pre-Exposure Prophylaxis PrEP The Fenway Institute trans Transgender Transgender Awareness Week Transgender Health Trans Health Trans Women Health Violence Recovery Program Women's Health Young Leaders Council young people